Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?

Hiralal, Rajesh; Koo, Karen K. Y.; Gerstein, Hertzel C.
April 2006
CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1090
Academic Journal
The article discusses research being done on the use of pioglitazone to prevent macrovascular events in patients with type 2 diabetes. With reference to a study by J. A. Dormandy et al, published in a 2005 issue of the journal "Lancet." Most patients with type 2 diabetes have a myriad of other metabolic and vascular abnormalities. The association of these metabolic disturbances with macrovascular disease is stated. In addition, this article assesses the effectiveness of the drug.


Related Articles

  • Vildagliptin: profile report. Mueller, Tanja; Barkun, Alan N // Drugs & Therapy Perspectives;Mar2007, Vol. 23 Issue 3, p4 

    Adapted and reproduced from Drugs 2006; 66 (15): 1989-2004[1-4]

  • Rimonabant: An Answer to Obesity in Diabetes? Kuritzky, Louis // Internal Medicine Alert;1/15/2007, Vol. 29 Issue 1, p7 

    The article discusses research being done on the effectiveness of rimonabant for obese patients with type 2 diabetes.

  • OPTIMUS-3: Prasugrel bested off-label doses of clopidogrel in small population of patients with type 2 diabetes. Raible, Eric; Rusk, Judy; Southall, Jennifer // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p43 

    The article discusses research on the efficacy of a 60-milligram (mg) loading dose and 10-mg maintenance dose of prasugrel against a 600-mg loading dose and 150-mg maintenance dose of clopidogrel in patients with type 2 diabetes and coronary artery disease, presented by Dominick Angiolillo at...

  • Happy brew year!  // Better Homes & Gardens;Jan2012, Vol. 90 Issue 1, p97 

    The article discusses the benefits of drinking coffee including protection against heart disease, type 2 diabetes, and some cancers.

  • People with type 2 diabetes who took the fat-blocking drug Xenical lowered their long-term heart disease risk.  // Environmental Nutrition;Jan2001, Vol. 24 Issue 1, p8 

    Reports on the reduction of the risk for heart disease in people with type 2 diabetes after taking the fat-blocking agent Xenical.

  • Antiosteoporotic Drugs and Incidence of Type 2 Diabetes Mellitus. Kanazawa, Ippei // Calcified Tissue International;Feb2012, Vol. 90 Issue 2, p163 

    No abstract available.

  • Prevalence of the Metabolic Syndrome and Its Components. Ilanne-Parikka, Pirjo; Eriksson, Johan G.; Lindström, Jaana; Hämäläinen, Helena; Keinänen-Kiukaanniemi, Sirkka; Laakso, Mauri; Louheranta, Anne; Mannelin, Marjo; Rastas, Merja; Salminen, Virpi; Aunola, Sirkka; Sundvall, Jouko; Valle, Timo; Lahtela, Jorma; Uusitupa, Matti; Tuomilehto, Jaakko // Diabetes Care;Sep2004, Vol. 27 Issue 9, p2135 

    Presents the study "Prevalence of the Metabolic Syndrome and Its Components." Statistics on the prevalence of type 2 diabetes worldwide; Risk facing subjects with abnormal glucose metabolism; Definition of the metabolic syndrome and its components; Results of the study.

  • Insulin Resistance And Syndrome X.  // Health & Stress;2002, Issue 5, p4 

    Reports on the link between insulin resistance and metabolic syndrome X. Symptoms and etiology of the syndrome; Prevalence of insulin resistance in patients with Type 2 diabetes; Factors mediating the complications of non-insulin dependent patients.

  • The Insulin-sensitizing Role of the Fat Derived Hormone Adiponectin. Heilbronn, L.K.; Smith, S.R.; Ravussin, E. // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 17, p1411 

    Adiponectin is an insulin-sensitizing hormone whose blood concentration is reduced in obesity and type 2 diabetes. Administration of recombinant adiponectin in rodents increases glucose uptake and increases fat oxidation in muscle, reduces fatty acid uptake and hepatic glucose production in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics